• American Fusion(TM) has appointed a government procurement advisor to expand access to non-dilutive funding channels, prioritizing defense, DOE, and international programs as early commercialization pathways.
• The company’s Texatron(TM) platform is being positioned for modular, infrastructure-grade applications, with government alignment reflecting a wider trend in fusion toward staged, program-based development.
• Institutional contracts may offer structured revenue opportunities before full-scale deployment.
• Engagement with NATO-linked and European programs signals a broader international strategy.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies recently announced it has engaged Samuel Reid as Government Strategy and Procurement Advisor, a step aimed at aligning its technology platform with procurement frameworks across defense, energy, and international agencies (https://ibn.fm/SK4CN).

Reid brings experience in multi-agency procurement systems, including work with NATO-affiliated organizations and the Canadian Department of National Defence. His background in structured contracting environments positions American Fusion(TM) to engage with programs where funding is tied to defined milestones, compliance standards, and long-term deployment objectives. For investors, this signals a shift from purely technical development toward institutional integration.

The strategy reflects a broader reality in the fusion sector. While commercial-scale fusion power remains under development, government programs, particularly those linked to national energy security and defense, have become a primary avenue for early funding and validation. These programs often provide non-dilutive capital, reducing reliance on equity markets while offering pathways to long-term contracts.

American Fusion(TM) appears to be aligning with this model. Management has indicated that U.S. Department of Energy programs, including public-private partnerships and lab-access initiatives, are central to its near-term engagement strategy. These programs are designed to support private-sector innovation while maintaining government oversight on critical technologies.

In parallel, the company is evaluating opportunities within defense procurement channels. Fusion-related technologies, even at an early stage, may have applications in resilient power systems, advanced materials, and energy infrastructure for military use. These areas are typically funded through structured procurement cycles, offering predictable frameworks for companies that can meet technical and regulatory requirements.

American Fusion(TM) is also extending its reach internationally. The company is evaluating opportunities within the European fusion ecosystem, including programs associated with ITER and related supply chains. Participation in such initiatives can provide access to engineering partnerships and procurement pipelines that are otherwise difficult to establish independently.

At the center of the company’s strategy is its Texatron(TM) platform, developed through its subsidiary, Kepler Fusion Technologies. The system is designed with a modular architecture, allowing deployment in standardized units that can scale over time. While still in development, this approach is intended to align with infrastructure planning models used by utilities and industrial operators.

According to company disclosures, Kepler is currently working on multiple system configurations, including a 5-megawatt demonstration unit and a 100-megawatt design that underpins its commercial roadmap. The modular concept allows capacity to be built incrementally: ten 100-MW units, for example, would equate to one gigawatt of generation.

The emphasis on modularity and institutional alignment is notable. Fusion remains a technically complex and capital-intensive field, with long development timelines. Companies that can integrate into existing procurement and funding ecosystems may be better positioned to manage these constraints.

Reid’s appointment is therefore less about immediate revenue and more about positioning. Government contracts, even at smaller scales, can provide validation, funding continuity, and access to infrastructure. They also tend to be less dilutive than traditional equity financing, a factor that can be material for early-stage companies.

The defense angle adds another layer. Energy resilience has become a priority for military and national security planning, particularly in scenarios where grid access is limited or unreliable. Fusion technologies, if successfully developed, could offer long-duration, high-density power in such contexts.

“The most immediate opportunity for companies operating in advanced energy is not large-scale deployment, but integration into existing government and institutional frameworks. The current landscape across Department of Energy programs, defense research channels, and international fusion initiatives is structured around enabling technologies, infrastructure development, and staged commercialization,” Reid said. “The focus is on positioning capabilities within those frameworks in a way that aligns with how funding and procurement decisions are actually made.”

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF)and may include paid advertising.

• The company has begun its 2026 exploration program at the Murdock Mountain Phosphate Project in northeastern Nevada after completing required wildlife and sage-grouse surveys.
• The company is preparing additional drill pads to expand understanding of the phosphate zone’s strike extent, thickness, continuity and grade characteristics.
• Murdock Mountain is a shallow-dipping, road-accessible sedimentary phosphate target zone that could support direct-application organic fertilizer production without chemical processing.
• Tightening global fertilizer supply, including LPG disruptions linked to instability in the Persian Gulf, may increase interest in phosphate projects that do not rely heavily on fossil-fuel-based inputs.
• Nevada Organic Phosphate is targeting the broader U.S. agricultural market, particularly the growing organic and regenerative farming sectors.

Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF), a B.C.-based leader in organic sedimentary phosphate exploration, is moving forward with its 2026 drill campaign at the Murdock Mountain Phosphate Project in northeastern Nevada, as the company seeks to advance one of the few known large-scale organic sedimentary phosphate target zones in North America.

The company announced on April 13 that all required wildlife and sage-grouse lek pre-clearance surveys tied to its exploration permit have been completed without issue, allowing site preparation to continue. The bulldozer contractor has returned to complete the remaining drill pads, after which drilling will resume to evaluate the strike extent, lateral continuity, thickness and grade of the phosphate zone exposed across the project area (https://ibn.fm/xz9TR).

Chief Executive Officer Robin Dow said maintaining schedule discipline remains central as the company advances the project toward its next technical milestones.

“Successful exploration requires multiple planning elements to align, and our team has excelled,” Director Garry Smith said, noting that the company secured a new drilling contractor, engaged a new environmental consultant and coordinated contractor mobilization under tight timelines.

The Murdock Mountain Project hosts a shallow-dipping sedimentary phosphate horizon with road access and proximity to transportation infrastructure, including the main highway to Montello and Elko, Nevada, as well as rail connections serving California and the East Coast.

That logistical advantage matters because Nevada Organic Phosphate’s business model is built around direct-ship raw rock phosphate rather than conventional chemically processed fertilizer inputs. Unlike traditional phosphate fertilizer production, which often depends on significant chemical treatment and fossil-fuel-intensive processing, the company’s product is designed for direct application to farmland after basic mining, grinding and bagging.

This approach aligns with the growing regenerative agriculture movement in the United States, where farmers increasingly seek reactive phosphate inputs rather than highly soluble chemical fertilizers. 

The company says its Murdock project contains a 6.6-kilometre phosphate bed, with additional applications extending the potential strike to more than 30 kilometres. Rather than focusing on conventional fertilizer markets, management is targeting the estimated $35 billion North American organic food sector, where demand for certified organic farming inputs continues to rise.

The economics of that strategy may become more relevant as global fertilizer supply chains face renewed strain. Recent geopolitical tensions in the Persian Gulf, including attacks affecting important LPG-linked infrastructure, have added pressure to fertilizer production markets that rely on liquefied petroleum gas and other fossil fuel inputs. LPG remains an important feedstock and energy source across parts of global fertilizer manufacturing, particularly for nitrogen and processed phosphate supply chains.

When energy-linked fertilizer inputs become more constrained or expensive, alternatives that require less industrial processing can become more attractive to both distributors and growers. That could support interest in companies like Nevada Organic Phosphate, whose phosphate model depends less on downstream chemical conversion and more on direct agricultural use.

The company highlights additional target areas beyond Murdock that could materially expand its long-term phosphate footprint in Nevada, though management remains focused on current drilling and geological definition. This year’s drilling is intended to extend the geological model established by 2025 core sampling, refine structural controls and improve confidence in the continuity of the phosphate-bearing zone.

For more information, visit the company’s website at www.NevadaPhosphate.com.

NOTE TO INVESTORS: The latest news and updates relating to NOP are available in the company’s newsroom at https://ibn.fm/NOP

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, remains bullish about the 2026 gold prices
• After an ongoing series of ups-and-downs, by mid-April the price of gold had worked its way past $4,840 per troy ounce to new all-time highs
• Some analysts have now projected that the price could hit $6,000/oz later in the year, mainly driven by geopolitical issues and continuing economic uncertainty
• ESGold expects to capitalize on this growth, accelerating development of its flagship Montauban project toward production
• It recently closed a C$7.2 million offering from the sale of 10,683,000 shares of the company, and looks to direct these proceeds to the development of this property

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, remains bullish about gold prices in 2026. Its management firmly believes that the precious metal will continue to grow in appeal as a safe alternative investment, particularly given the unavoidable factors driving up its price, including but not limited to unending geopolitical and debt issues feeding growing economic uncertainty.

Thus far, these factors have, despite unavoidable volatility, driven up gold prices to increasing all-time highs. By mid-April, the precious metal, for the first time in history, surpassed $4,840 per troy ounce, with some experts projecting that it could reach $6,000 at some point in 2026. In a report published by J.P. Morgan in December 2025, it was projected that prices would rise toward $5,000/oz by Q4 2026 and toward $6,000/oz in the longer term. This has been accelerated by geopolitical issues, which have increased economic uncertainties already fueled by rising worldwide debt (https://ibn.fm/Yj7yu).

“While this rally in gold has not, and will not, be linier, we believe the trends driving this rebasing higher in gold prices are not exhausted,” noted Natasha Kaneva, head of Global Commodities Strategy at J.P. Morgan.

“The long-term trend of official reserve and investor diversification into gold has further to run,” she added (https://ibn.fm/Yj7yu).

To capitalize on this growth, ESGold has embarked on developing its Montauban flagship project. As a past—producing mine, the property is yet to be fully explored, and its potential is yet to be fully tapped. While speaking on an episode of The MiningNewsWire Podcast, Gordon Robb, ESGold’s CEO, noted how the company is in such an opportune time and how it has positioned itself to take advantage of this growing market.

“This is a past-producing mine that produced for well over 100 years with very limited property-wide exploration….That leaves us with a very exciting opportunity, because this is a known mine that has never had modern exploration techniques applied across the entire property,” he noted. “2026 is a very big year for us. We have secured all our equipment…We’re currently building out our facility at a very fast pace. We’re aiming to be in operations this year, coupled with our maiden drill campaign kicking off. I can confidently say for myself and my team, there’s not a lot of sleep going on, but this is a very exciting period for us as we move quickly toward these major milestones,” he added (https://ibn.fm/7XMlZ).

Mr. Robb’s statement follows ESGold’s recent close of a C$7.2 million offering, in which the company sold 10,683,000 units at C$0.68 per unit. These proceeds will accelerate the company’s plans going forward, especially given that it has a million metric tons of material on the surface of its Montauban property that needs to be processed (https://ibn.fm/9yj28).

“We have a million metric tons of material on surface that needs to be processed, and we’re currently building out our facility so we’re operational and generating cash flow while simultaneously expanding the exploration package,” Robb noted (https://ibn.fm/7XMlZ).

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

Voice Analytics and AI to Transform Drug and Alcohol Testing

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising.

• MindBio Therapeutics is developing AI-driven voice analysis technology to detect drug and alcohol impairment without relying on invasive and time-consuming breath, saliva, or laboratory testing.
• The company’s platform analyzes more than 140 acoustic markers and is trained on over 50 million data points to estimate intoxication levels from short voice samples.
• The new technology is seen applicable to both workplace and non-workplace settings, with the global alcohol and drug testing devices market projected to grow from $2.5 billion in 2025 to $4.2 billion by 2033, reflecting rising safety requirements and stricter regulatory oversight.
• Mining is MindBio’s initial commercial focus, particularly in South America, where large workforces and high-risk operating environments create demand for rapid impairment screening, with other areas of application including aviation, construction, call centers, law enforcement, and mental health settings where high-volume screening is expensive and time consuming.

The market for workplace drug and alcohol detection is expanding as employers face increasing pressure to improve safety while reducing the cost and friction of traditional testing methods. This creates a unique opportunity for companies attempting to modernize a process that remains heavily dependent on breathalyzers, urine testing, and laboratory analysis.

MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company, is positioning itself in that space with an alternative approach: using artificial intelligence and voice analytics to estimate drug and alcohol intoxication levels from short speech samples. The company has spent several years conducting drug and alcohol research while developing machine learning models designed to detect impairment through speech. Rather than relying on physical samples such as breath, saliva, or blood, the system analyzes voice patterns captured through a standard microphone.

Management says the platform evaluates more than 140 acoustic parameters and has been trained using a dataset exceeding 50 million data points. The goal is to identify measurable speech changes associated with intoxication and deliver a rapid assessment in real time.

Traditional workplace testing is often expensive, disruptive, and difficult to scale. In industries with thousands of workers entering safety-sensitive environments every day, routine alcohol and drug testing can create operational bottlenecks and significant administrative costs. This is particularly relevant in mining, aviation, construction, and transportation, where regulators often require formal testing protocols and where a single impairment-related incident can carry serious human and financial consequences.

According to market research published by Data Insights Market, the global alcohol and drug testing devices market is expected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, representing a 7% compound annual growth rate. (https://ibn.fm/0dkYp). That growth is being driven by stricter workplace compliance rules, increasing concerns around substance misuse, and wider adoption of point-of-care testing that allows immediate results rather than delayed laboratory reporting.

Portable and handheld systems are gaining share because employers increasingly want testing solutions that can be used in remote locations or high-volume environments. This trend aligns with MindBio’s development of Edge AI kiosks intended for industrial deployment.

The proposed use case is simple. A worker arriving at a mine site, construction project, or industrial facility would provide a short voice sample at an entry point kiosk. The system would then analyze the recording and flag indicators of alcohol or drug impairment almost immediately. This could reduce dependence on invasive testing procedures and allow management to screen larger workforces more efficiently. It may also help address one of the persistent limitations of conventional testing: the balance between compliance and productivity.

MindBio’s initial commercial focus has been on the mining industry, particularly operations in South America. These sites often involve remote locations, rotating workforces, and high-risk physical tasks where fatigue, impairment, and human error can create outsized operational risks.

The company has indicated that field testing of its kiosk systems is expected during the second quarter of 2026. If successful, that could provide an important commercial validation point for investors assessing whether the technology can move beyond development and into enterprise adoption.

The opportunity, however, extends beyond mining. Management has identified call centers, law enforcement, and mental health settings as additional target markets, alongside regulated sectors such as aviation and construction. In these environments, high-volume screening can be difficult to administer using traditional methods.

Call centers, for example, face challenges related not only to alcohol and drug use but also to fatigue, stress, and mental wellness. Voice analytics may provide employers with another operational tool where speech is already central to the work environment. Law enforcement agencies and mental health services may also benefit from rapid, non-invasive assessment tools where behavioral indicators matter but immediate laboratory testing is impractical.

For more information, visit the company’s website at www.MindBioTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF

• Oncotelic’s PDAOAI platform indexes 125,000+ PubMed abstracts on TGF-β signaling, enabling researchers to interrogate the evidence for testable, auditable hypotheses rather than rely on black-box predictions.
• Recent industry coverage places Oncotelic alongside Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector’s shift toward AI-integrated operations.
• The hypothesis-first approach addresses a core challenge in biotech research: reducing training-set bias and building transparent, reproducible chains from question to evidence to hypothesis.

Pharmaceutical research and manufacturing are undergoing a structural transition. Regulatory agencies are raising expectations around data integrity and traceability, while the industry is shifting from retrospective audits toward continuous, AI-enabled monitoring systems. At the same time, drug discovery is being reshaped by the growing availability of large-scale biomedical data and the tools to interrogate it at scale. Both shifts reflect a common underlying reality: manual processes and isolated datasets are no longer sufficient in an environment where scientific literature expands rapidly and regulatory expectations demand continuous, defensible documentation. Oncotelic Therapeutics (OTCQB: OTLC) has responded to this environment with PDAOAI, an evidence-interrogation platform designed to surface testable research hypotheses from the global TGF-β literature.

What PDAOAI Does Differently

Instead of relying on traditional predictive models trained to replicate historical datasets, PDAOAI takes a retrieval-and-interrogation approach. The platform organizes and connects large volumes of biomedical literature, enabling researchers to identify patterns and generate testable hypotheses with direct links to underlying source data.

Each output is tied back to its originating evidence, creating an auditable chain from question to evidence to hypothesis. This distinction is increasingly relevant as concerns grow around model transparency, reproducibility, and training-set bias in biomedical AI. By positioning itself as an interrogation layer rather than a black-box predictor, Oncotelic is aligning its platform with the practical requirements of research environments where every conclusion must be validated and defensible.

The TGF-β Corpus

The platform’s initial deployment focuses on a corpus of more than 125,000 PubMed abstracts centered on transforming growth factor beta (“TGF-β”), a signaling pathway implicated in cancer progression, immune response, fibrosis, and metabolic disease. TGF-β is also the scientific foundation of Oncotelic’s lead therapeutic candidate, OT-101, a first-in-class anti-TGF-β RNA-based therapy.

By structuring and analyzing this body of literature, PDAOAI allows researchers to move beyond keyword searches to explore relationships across datasets, identifying recurring biological patterns and potential mechanistic links that may inform future development strategies.

A Broader Industry Transition

The context for Oncotelic’s platform extends beyond drug discovery. A recent editorial positioned the company within a broader group of organizations contributing to the integration of artificial intelligence across pharmaceutical and life sciences operations. This group includes Rockwell Automation Inc., Emerson Electric Co., Thermo Fisher Scientific Inc., and Danaher Corp., each advancing AI-enabled systems across industrial and laboratory environments.

Parallel developments are taking place in manufacturing. Nightfood Holdings Inc., operating as TechForce Robotics, has advanced AI-enabled robotic systems designed to automate sterile manufacturing environments, reinforcing the industry’s shift toward integrated, real-time compliance systems.

Together, these developments reflect a wider transition toward interconnected, intelligent systems across the pharmaceutical value chain, spanning both research and production.

Why the Positioning Matters

Regulatory frameworks such as the European Union’s updated GMP Annex 1 and initiatives from the U.S. Food and Drug Administration are encouraging the adoption of continuous monitoring, embedded intelligence, and automated documentation. These changes are contributing to what is increasingly described as Pharma 4.0, an environment where data flows continuously across systems and compliance is integrated into every stage of the process.

While PDAOAI operates at the discovery and hypothesis-generation stage rather than in manufacturing, the underlying principle is consistent: replacing fragmented, manual processes with systems that are continuously auditable, reproducible, and resistant to bias.

For Oncotelic, this positioning connects its therapeutic pipeline, including OT-101 and its focus on rare and underserved indications, to a broader infrastructure shift occurring across the industry.

Closing Perspective

As artificial intelligence continues to expand across both discovery and manufacturing environments, platforms that enable traceable, reproducible, and evidence-based decision-making are becoming central to pharmaceutical development.

Within this evolving framework, PDAOAI reflects a model focused not on prediction alone, but on structured interrogation of the underlying evidence – a distinction that may become more important as the industry places greater emphasis on transparency, validation, and data integrity.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.

• Planet Ventures is increasing its exposure to AI-driven space infrastructure through strategic investment in Antaris
• The company is positioning itself at the intersection of orbital computing, satellite software, and the next frontier
• These moves underscore a broader industry shift toward space-based data infrastructure and lunar-enabling technologies

Planet Ventures (CSE: PXI) (OTC: PNXPF) (FSE: P6U) is aligning itself with one of the transformative trends in modern technology: the convergence of space infrastructure and artificial intelligence. With global demand for computing power increasing and terrestrial constraints on energy, cooling, and land becoming more pronounced, a new frontier is quickly emerging – orbital data systems and space-based compute networks capable of supporting next-generation AI applications.

Recent developments in the industry highlight the urgency and scale of this transition. For example, SpaceX has recently filed plans for a massive orbital data-center constellation, possibly deploying up to 1 million satellites designed to power AI workloads in space (ibn.fm/FV8XX). This concept leverages solar energy and the vacuum of space for cooling, positioning orbit as a potentially more efficient solution for high-performance computing. SpaceX’s integration with xAI signals a strategic effort to unify AI demand with space-based delivery infrastructure, reinforcing the idea that space could become a foundational layer of the global compute stack (ibn.fm/HLSoo).

While analysts suggest significant economic and engineering challenges ranging from the complexity of maintaining large-scale orbital systems to radiation impacts on hardware, the broader industry consensus is moving from “if” to “when.” Crucially, this evolution is not just limited to low Earth orbit. It is increasingly tied to renewed global interest in lunar development, where resilient communications, real-time data processing, and autonomous systems will be important for sustained human and robotic presence. 

Planet Ventures Inc. is implementing a focused investment strategy targeted at capturing early-stage value in the quickly evolving space economy. In early April, the company made a strategic investment in Antaris, following a $28 Million Series A Financing, a platform that enables full mission virtualization from design to simulation to deployment and operations (ibn.fm/I2pfB). The software-centric approach is quickly becoming vital as satellite constellations become more complex, supporting capabilities such as predictive modeling, anomaly detection, and autonomous mission management.

Operating at the intersection of disruptive innovation and venture capital, Planet Ventures is aligning its portfolio with sectors where automation, AI, and space infrastructure converge. As industry shifts toward orbital computing and lunar-linked technologies, the company’s early positioning reflects a broader strategy to participate in building the foundational infrastructure of not only a multi-trillion-dollar space economy, but the next frontier of technology.

For more information, visit www.PlanetVenturesInc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

Disclaimer

Investor Brand Network (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Planet Ventures Inc. will make aggregate payments of $100,000  to us to provide marketing services for a term of 1 year. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of applicable securities legislation, including statements regarding Planet Ventures’ investment strategy, anticipated market developments, the projected growth of the global space economy, the expected timelines and milestones of portfolio companies including Mantis Space and GRU Space, the anticipated economic impact of Mantis Space’s operations, and the role of Tansu Yegen as strategic advisor. Forward-looking statements are based on the current expectations, estimates, forecasts, and projections of Planet Ventures’ management and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements.

Forward-looking statements are not guarantees of future performance. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this document are made as of the date hereof and Planet Ventures undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

Risk Factors

Investing in Planet Ventures and its portfolio companies involves a high degree of risk. The following is a summary of key risk factors. This is not an exhaustive list, and additional risks may exist that are not currently known:

• Early-Stage Investment Risk. Portfolio companies have limited operating histories and are pre-revenue. Investments are speculative and may result in a total loss of capital.
• Technology Risk. The orbital energy and lunar habitation technologies underlying the Company’s investments are unproven at commercial scale and may not be successfully developed or deployed.
• Regulatory Risk. Space sector operations require licenses and approvals from domestic and international regulatory bodies. Failure to obtain or maintain these could materially delay or prevent operations.
• Market Risk. Commercial demand for in-space power systems and lunar services has not been established at scale. Projected market growth may not be realized within anticipated timeframes.
• Liquidity Risk. Investments in private, early-stage companies are illiquid. There is no guarantee of a market for these securities or the ability to exit on favorable terms.
• Capital Risk. Portfolio companies may require additional funding that may not be available, or may be available only on dilutive or restrictive terms.
• Macroeconomic and Geopolitical Risk. Adverse macroeconomic conditions or geopolitical developments could disrupt the Company’s investment strategy or the operations of portfolio companies.
• Key Personnel Risk. The Company’s performance depends in part on retaining key personnel and advisors. Loss of key individuals could adversely affect the Company’s operations and investment activities

• The scale and impact of cardiovascular disease underscore why innovation in this area is so critical.
• Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression.
• By utilizing a simple blood test, Cardio Diagnostics is lowering barriers to advanced cardiovascular testing.

Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (“AI”) and multi-omic biomarkers to deliver actionable insights from a simple blood sample, enabling more informed and timely care cardiac care decisions.

The scale and impact of cardiovascular disease underscore why innovation in this area is so critical. According to the Centers for Disease Control and Prevention, heart disease remains the leading cause of death in the United States, responsible for approximately one in every three deaths. Beyond mortality, the economic burden is substantial. In the United States alone, cardiovascular disease costs the healthcare system $233 billion annually in direct medical costs and an additional $185 billion in lost productivity, with total costs projected to approach $2 trillion by 2050. These numbers highlight the importance of improving both prevention and treatment strategies.

Despite advances in medicine, a key challenge in managing cardiovascular disease is that it often develops silently over many years before symptoms appear. Traditional risk assessment tools rely heavily on clinical factors such as cholesterol levels, blood pressure and lifestyle indicators. While useful, these measures can fail to capture the underlying biological changes that can precede disease onset. Studies indicate that many cardiovascular risks and related conditions remain undiagnosed or unrecognized, with significant gaps in screening leaving large portions of at-risk individuals unidentified, underscoring limitations in current risk assessment approaches.

This gap has driven increasing interest in precision medicine approaches that incorporate molecular-level data to improve risk prediction and help guide treatment. Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression. Cardio Diagnostics is applying these principles through its proprietary platform, which combines epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights. The company’s platform is designed to analyze molecular signals captured in a blood sample and translate them using AI into clinically relevant information that can support earlier intervention and more targeted treatment planning.

One of the key advantages of this approach is its ability to detect biological changes before they may manifest as clinical symptoms. Epigenetic markers, such as DNA methylation patterns, can reflect the cumulative impact of lifestyle, environmental exposures and disease processes on gene expression. Research has shown that these markers can serve as early indicators of disease risk, providing a window of opportunity for preventive action.

Artificial intelligence plays a central role in making sense of this complex data. Machine learning algorithms can analyze large, multidimensional datasets to identify patterns associated with disease risk and progression. Studies report that AI has the potential to improve diagnostic accuracy and enable more personalized care by uncovering relationships that are not readily apparent through traditional methods. By applying AI to integrated genetic and epigenetic data, Cardio Diagnostics aims to provide clinicians with more precise and actionable insights.

Another important aspect of the company’s platform is its accessibility. By utilizing a simple blood test, Cardio Diagnostics is lowering barriers to advanced cardiovascular testing. This is particularly relevant in the context of ongoing efforts to expand preventive care and improve patient engagement. Blood-based diagnostics can be more easily incorporated into routine clinical workflows, enabling broader adoption and more consistent monitoring over time.

The ability to generate personalized insights also has implications for treatment. Rather than relying on generalized markers, clinicians can use patient-specific molecular data to tailor interventions, potentially improving outcomes and reducing unnecessary treatments. This aligns with a broader shift in healthcare toward individualized care models that prioritize both effectiveness and efficiency.

In addition to supporting early detection, platforms such as the one developed by Cardio Diagnostics may also play a role in ongoing disease management. By tracking molecular changes over time, clinicians can gain a better understanding of how a patient is responding to treatment and adjust as needed. This dynamic approach reflects an evolving view of cardiovascular care as a continuous process rather than a series of isolated events.

As the health-care industry continues to embrace data-driven approaches, the integration of multi-omic biomarkers and AI is expected to become increasingly important. Cardio Diagnostics Holdings is contributing to this transformation by developing tools that aim to bridge the gap between early detection and effective treatment. By providing deeper insights into the biological drivers of cardiovascular disease, the company is helping to support a more proactive and personalized approach to care.

For more information, visit www.CDIO.ai.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

• Safe Pro Group recently began the commercial rollout of NODE-X, a next-gen miniaturized AI-powered edge compute processor of drone footage for threat detection.
• The rollout began at a U.S. Army Exercise, and NODE-X is scheduled to be a part of additional U.S. Army exercises throughout the second quarter of 2026.
• NODE-X is powered by Safe Pro’s patented Safe Pro Object Threat Detection (“SPOTD”), a powerful technology used to rapidly analyze drone imagery and video to identify and detect small explosive threats.

Safe Pro Group (NASDAQ: SPAI), a developer of AI-enabled security, defense, and situational awareness solutions, recently started the commercial rollout of NODE-X at a U.S. Army exercise (https://ibn.fm/5IdSl).

Node-X is a next-gen miniaturized AI-powered edge compute processor of drone footage for detecting threats in military support missions. This solution is the next generation of Safe Pro’s AI-powered ecosystem of tools that enable the rapid processing of drone images and videos for AI threat detection, 3D mapping, and route guidance.

The Node-X is designed as a backpack-sized kit that includes real-time AI inference on an edge compute server, as well as rugged GPU laptops running Safe Pro’s OnSight application, which is compatible with U.S. Army-approved short-range recon (“SRR”) drones.

Node-X is powered by Safe Pro’s Safe Pro Object Threat Detection (“SPOTD”), which is a platform that rapidly analyzes videos and images from virtually any drone to detect and classify explosive threats and other small objects of interest. 

The platform converts raw video into high-resolution 2D/3D models that can quickly be shared to support operational decision-making and provide better situational awareness.

Node-X uses AI and machine learning algorithms that are trained on one of the world’s largest imagery datasets from Ukraine, which includes 2.6 million drone images and 47,000 confirmed detections of small threats like landmines, cluster munitions, ambush drones, and unexploded ordnance (“UXO”).

It operates on the edge without any need for connectivity and incorporates AI-detected threats with the fast generation of 3D models and digital surface models, such as terrain slope, vegetation height, and more.

The field-deployable design and intuitive interface of the solution provides both soldiers and military commanders with important situational awareness, which makes it an ideal piece of tech for a variety of different missions.

The Node-X is scheduled to take part in additional U.S. Army exercises through the second quarter of 2026, as Safe Pro builds momentum towards rapid expansion.

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that develops and delivers advanced AI-powered security and defense solutions to customers in the law enforcement, defense, homeland security, and humanitarian industries. At the core of Safe Pro’s mission is a patented computer vision software technology used to rapidly and accurately detect small threats and objects in drone photos and videos, to boost the safety of field operations for ground teams.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Integrated geochemical and geophysical data point to structurally controlled mineralization at Atikokan rare earth property.
• Dashwa Gneiss Complex emerges as the primary focus for follow-up work.
• Soil, rock, and sediment sampling indicate consistent rare earth element (“REE”) anomalies.
• Results support a coherent exploration model rather than isolated occurrences.
• The project aligns with rising strategic demand for domestic REE supply in North America.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth projects across North America, has refined its exploration strategy at the Atikokan Rare Earth Property in northwestern Ontario, identifying priority target zones following a comprehensive integration of geochemical assays and geophysical data. The findings mark a shift from early-stage sampling toward more targeted exploration planning (https://ibn.fm/hbas0).

The company’s latest interpretation combines results from rock, soil, and sediment sampling with airborne magnetic and radiometric surveys conducted in 2025. This dataset has enabled Powermax to delineate zones where rare earth element (“REE”) mineralization may be structurally concentrated, rather than dispersed.

Two distinct geological environments have been identified across the property. The Dashwa Gneiss Complex, covering Blocks B and C, has been prioritized for follow-up exploration. In contrast, the White Otter Batholith, designated as Block A, has been assigned lower priority due to weaker geochemical correlations and more diffuse mineralization patterns.

Sampling results provide the basis for this distinction. Rock samples returned total rare earth oxide (“TREO”) values ranging from 19.1 to 503.3 parts per million, with several readings exceeding 200 ppm. Soil samples showed values up to 615.8 ppm, while sediment samples indicated downstream dispersion of REE-bearing material. These figures fall within ranges typically associated with early-stage exploration systems but show consistent anomaly clustering.

More significant for exploration planning is the spatial relationship of these anomalies. Elevated REE values appear linked to structural corridors, shear zones, and lithological contacts: features that can act as conduits for mineralizing processes. This pattern supports a structurally controlled model, where mineralization is concentrated along deformation zones rather than evenly distributed.

The company’s interpretation also highlights geochemical associations between REEs, thorium, and uranium. Such correlations are commonly used as vectors in rare earth exploration, helping geologists trace surface anomalies back to potential subsurface concentrations. In this case, the presence of minerals such as monazite and allanite, both known hosts for light rare earth elements, reinforces the working model.

The technical work underpinning these findings is extensive. The 2025 program included airborne surveys flown at 50-metre line spacing, along with ground-based mapping, prospecting, and systematic sampling. A total of 426 samples were collected and analyzed by AGAT Laboratories Ltd. using sodium peroxide fusion and ICP-OES/MS methods, providing near-total digestion for REE analysis. Quality control procedures included duplicates, blanks, and standards to ensure data reliability.

Powermax’s approach reflects a broader trend in early-stage mineral exploration, where integrated datasets are used to reduce geological uncertainty before advancing to more capital-intensive drilling campaigns. By combining multiple data types, companies aim to increase the probability of targeting zones with meaningful mineralization.

The strategic context for rare earth elements adds another layer of relevance. Global demand for REEs, critical components in electric vehicles, wind turbines, and advanced electronics, is projected to rise significantly over the next decade. At the same time, supply chains remain heavily concentrated, with China controlling a substantial share of both mining and processing capacity.

This imbalance has prompted policy responses in North America and Europe, including funding initiatives and incentives aimed at developing domestic supply. In the United States, mechanisms such as the Defense Production Act have been used to direct capital toward critical mineral projects, while Canadian companies may also benefit from cross-border collaboration and funding eligibility.

Within this environment, exploration-stage projects such as Atikokan are being evaluated not only on geological merit but also on their potential role in diversifying supply chains. However, it is important to note that the project remains at an early stage. The current results define exploration targets rather than confirmed economic mineralization.

Powermax holds a portfolio of REE-focused properties across Canada and the United States, including projects in British Columbia and Wyoming. The Atikokan property, comprising 455 unpatented mining claims, represents one of its more advanced exploration efforts in terms of integrated data analysis.

The next phase of work is to focus on refining these targets through additional field studies and, potentially, initial drilling campaigns. Such steps will be necessary to determine whether the identified anomalies translate into continuous mineralized zones with economic potential.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

• At the core of Cardio Diagnostics’ approach is the use of artificial intelligence to integrate multi-omic data to provide a more comprehensive view of cardiovascular health.
• The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk.
• CDIO’s focus on accessibility and scalability is also notable.

Cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. Cardio Diagnostics Holdings (NASDAQ: CDIO) is at the forefront of this shift, developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk assessments from a simple blood sample.

At the core of Cardio Diagnostics’ approach is the use of AI to integrate multi-omic data, specifically epigenetic markers such as DNA methylation with genetic information, to provide a more comprehensive view of cardiovascular health. Traditional diagnostic tools often rely on population-based risk factors such as cholesterol levels, blood pressure and family history. While these indicators are valuable, they may not fully capture individualized disease risk or early molecular changes of disease that precede clinical symptoms. By contrast, epigenetic biomarkers reflect how environmental and lifestyle factors influence gene expression, offering a dynamic layer of insight that evolves over time.

The scientific foundation for this approach is well supported. Research published by the National Institutes of Health highlights that DNA methylation patterns can serve as sensitive indicators of disease risk and biological aging, with applications in cardiovascular conditions. These epigenetic modifications can reveal early disruptions in biological pathways long before structural changes or symptoms may appear, making them particularly valuable for preventive care and early intervention.

Cardio Diagnostics’ platform builds on this concept by combining epigenetic and genetic data with AI algorithms designed to detect complex patterns across large datasets. AI has increasingly been recognized as a powerful tool in healthcare for identifying relationships that may not be apparent through conventional statistical methods. A report from National Academy of Medicine notes that AI can enhance clinical decision-making by uncovering subtle correlations in biomedical data and improving risk prediction models. By applying machine learning to multi-omic inputs, Cardio Diagnostics aims to deliver more accurate and individualized assessments than traditional models.

The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk. This approach simplifies the diagnostic process while improving precision. The use of a blood-based test is particularly important, as it reduces barriers to testing and enables broader accessibility compared to more invasive or resource-intensive diagnostic procedures.

The integration of multiple biomarker types is also a key differentiator. Genetic markers provide information about inherited set points in key biological pathways, while epigenetic markers capture real-time biological responses to factors such as diet, stress and environmental exposures. Together, these data layers create a more complete picture of cardiovascular health. 

This aligns with broader trends in precision medicine, where combining diverse data sources has been shown to improve predictive accuracy. The National Human Genome Research Institute emphasizes that both genomic and epigenomic research enhance the understanding of complex diseases and support more personalized approaches to care, including tailoring treatment based on individual molecular profiles.

Artificial intelligence serves as the analytical engine that makes this integration possible. Machine learning models can process high-dimensional datasets and continuously improve as more data becomes available. This capability is essential when working with epigenetic information, which can vary widely between individuals and over time. By training algorithms on large datasets, platforms such as the one developed by Cardio Diagnostics can identify patterns associated with disease risk or presence of disease and translate them into clinically relevant insights.

The company’s focus on accessibility and scalability is also notable. Blood-based diagnostics are among the fastest-growing segments in precision medicine, driven by their convenience and potential for early detection. A “Nature Medicine Journal” article reports that liquid biopsy approaches, which analyze biomarkers in blood, are increasingly being used to detect and monitor diseases with high sensitivity and specificity. While much of the early work has focused on oncology, similar principles are now being applied to cardiovascular disease, where early detection can significantly influence outcomes.

Cardio Diagnostics’ platform reflects a broader shift toward proactive health care, where the goal is not only to diagnose disease but to predict and prevent it. By leveraging epigenetic and genetic data, the company aims to move beyond static risk assessments and provide insights that evolve with the patient. This dynamic approach has the potential to support more timely interventions and better-informed clinical decisions.

In addition to its technological foundation, CDIO’s platform is designed to fit within existing health-care workflows. The simplicity of a blood test, combined with AI-driven analysis, allows for integration into routine care settings without requiring extensive new infrastructure. This is particularly important as healthcare systems increasingly seek solutions that can scale efficiently while maintaining high levels of accuracy and reliability.

As precision medicine continues to advance, the integration of multi-omic data and artificial intelligence is expected to play a central role in the future of diagnostics. Cardio Diagnostics Holdings is positioning itself within this emerging landscape by developing a platform that combines scientific rigor with practical usability. By translating complex molecular data into actionable insights, the company is contributing to a new generation of diagnostic tools aimed at improving how cardiovascular risk and disease are assessed and managed.

For more information, visit www.CDIO.ai.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO